Several other research firms also recently commented on BYSI. Seaport Global Securities began coverage on shares of BeyondSpring in a report on Tuesday, December 5th. They issued a buy rating and a $56.00 price objective for the company. HC Wainwright set a $60.00 price objective on shares of BeyondSpring and gave the stock a buy rating in a report on Monday, December 4th. Finally, Zacks Investment Research raised shares of BeyondSpring from a sell rating to a hold rating in a report on Tuesday, January 9th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $54.50.
BeyondSpring stock opened at $26.25 on Monday. BeyondSpring has a fifty-two week low of $18.50 and a fifty-two week high of $48.49.
WARNING: “BeyondSpring (BYSI) Given a $52.00 Price Target by Maxim Group Analysts” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://ledgergazette.com/2018/03/20/beyondspring-bysi-given-a-52-00-price-target-by-maxim-group-analysts.html.
BeyondSpring Company Profile
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.